Clinical Pharmacokinetics of the Antiandrogens and Their Efficacy in Prostate Cancer
- 1 January 1998
- journal article
- review article
- Published by Springer Science and Business Media LLC in Clinical Pharmacokinetics
- Vol. 34 (5), 405-417
- https://doi.org/10.2165/00003088-199834050-00005
Abstract
No abstract availableKeywords
This publication has 53 references indexed in Scilit:
- High failure rate associated with long‐term follow‐up of neoadjuvant androgen deprivation followed by radical prostatectomy for stage C prostatic cancerBritish Journal of Urology, 1995
- Neoadjuvant hormonal therapy and radical prostatectomy for clinical stage C carcinoma of the prostateBritish Journal of Urology, 1994
- Effect of the nonsteroidal antiandrogen nilutamide on adrenal androgen secretionThe Prostate, 1994
- Nilutamide pneumonitis: a report on eight patients.Thorax, 1992
- A Controlled Trial of Leuprolide with and without Flutamide in Prostatic CarcinomaNew England Journal of Medicine, 1989
- Prevention of the Transient Adverse Effects of a Gonadotropin-Releasing Hormone Analogue (Buserelin) in Metastatic Prostatic Carcinoma by Administration of an Antiandrogen (Nilutamide)New England Journal of Medicine, 1989
- Pharmacology of antiandrogensJournal of Steroid Biochemistry, 1986
- Ocular toxicity of Anandron in patients treated for prostatic cancer.British Journal of Ophthalmology, 1986
- COMBINED TREATMENT WITH BUSEREUN AND CYPROTERONE ACETATE IN METASTATIC PROSTATIC CARCINOMAThe Lancet, 1985
- Treatment of Advanced Prostatic Cancer with Parenteral Cyproterone Acetate: A Phase III Randomised Trial*British Journal of Urology, 1980